|
A Pharmacokinetic and Pharmacodynamic Study of Vincristine in Children with Leukemia Clinical Trials Information presented on Clinical Trials Search is not designed to be a substitute for certified medical advice, trips or professional assistance with a real medical doctor. We aren't docs. Always confer with your doctor about A Pharmacokinetic and Pharmacodynamic Study of Vincristine in Children with Leukemia conditions. Clinical Trials Search.org is a website committed to listing clinical research studies in human subjects. A Pharmacokinetic and Pharmacodynamic Study of Vincristine in Children with Leukemia Clinical research trials and A Pharmacokinetic and Pharmacodynamic Study of Vincristine in Children with Leukemia health trials happen in many of cities across the US. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials generally measure the effectualness of new does drugs. The intention of the studies / projects is to figure out particular human healthcare questions. Clinical trials are a popular manner for doctors, government agencies, and private sector corporations to detect cures for all forms of circumstances, like A Pharmacokinetic and Pharmacodynamic Study of Vincristine in Children with Leukemia. A Pharmacokinetic and Pharmacodynamic Study of Vincristine in Children with Leukemia Clinical Trials and other clinical trials allow for volunteers to undergo medical treatment options before they are available to the general public. Most times the subjects get treatment for free of charge, and occasionally they are paid for their time. Occasionally there is a cost for a A Pharmacokinetic and Pharmacodynamic Study of Vincristine in Children with Leukemia clinical trial. Subjects frequently get the best healthcare possible for their A Pharmacokinetic and Pharmacodynamic Study of Vincristine in Children with Leukemia condition. Hazards are a reality, however, and could include more or frequent mD visits, health risks (possibly life-jeopardizing), and/or the treatment being ineffectual. Trials are federally regulated with exacting guidelines to protect clinical trials patients.
|
|
|
|
|
|
|
Home > "A" Clinical Trials Conditions > A Pharmacokinetic and Pharmacodynamic Study of Vincristine in Children with Leukemia  A Pharmacokinetic and Pharmacodynamic Study of Vincristine in Children with Leukemia
A Pharmacokinetic and Pharmacodynamic Study of Vincristine in Children with Leukemia
For Condition: Acute Lymphocytic Leukemia,Leukemia
Status: Completed
Sponsor(s): National Cancer Institute (NCI) ,
Synopsis: The pharmacokinetic behavior of vincristine in pediatric patients has not been well characterized. The present study will obtain detailed information on vincristine pharmacokinetics in patients being treated for standard risk ALL on CCG protocols 1952/1962. A limited sampling strategy will be developed, and the interpatient and intrapatient variability of vincristine pharmacokinetics in children will be studied. A correlation between vincristine neurotoxicity and vincristine pharmacokinetics will be sought.
Details: The pharmacokinetic behavior of vincristine in pediatric patients has not been well characterized. The present study will obtain detailed information on vincristine pharmacokinetics in patients being treated for standard risk ALL according to or on CCG protocols 1952/1962/1991. A limited sampling strategy will be developed, and the interpatient and intrapatient variability of vincristine pharmacokinetics in children will be studied. A correlation between vincristine neurotoxicity and vincristine pharmacokinetics will be sought.
Eligibility:
Study Type: Interventional, Treatment, Safety
Minimum Age/Maximum Age: /
Genders: Both
Protocol Entry Criteria: INCLUSION CRITERIA: All patients 1 year and less than 10 years of age. Patient must be diagnosed with acute lymphoblastic leukemia. All CCG patients must be enrolled on CCG 1952, 1962 or 1991 protocols, or be treated according to a CCG standard risk ALL protocol. NCI patients must be treated according to CCG 1952 for the treatment of standard risk ALL. Enrollment onto the current trial (CCG B9802) should if possible take place concurrently with enrollment onto 1952/1962/1991 or start of treatment according to a CCG standard risk ALL protocol. All patients or their legal guardians must sign a document of informed consent indicating their awareness of the investigational nature and the risks of this study. EXCLUSION CRITERIA: Previous underlying peripheral neuropathy. Previous underlying central nervous system dysfunction. Children with CNS toxicity attributable to other chemotherapeutic agents will not be followed with the Purdue pegboard test.
Total Enrollment: 90
Location and Contact Information:
National Cancer Institute (NCI)
Bethesda, Maryland, 20892
United States
Additional Information:
Study ID Numbers: 980053; 98-C-0053
Study Start Date: January 22, 1998
Record last reviewed: November 26, 2003
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00001689
Other Acute Lymphocytic Leukemia Studies:
1. Phase I Study of Intrathecal Topotecan
2. Evaluation, Treatment, and Natural History of Children with Cancer
3. Growth Factor to Prevent Oral Mucositis in Patients With Hematologic Cancer
4. Biological Therapy in Treating Patients Undergoing Radiation Therapy, Chemotherapy, and Peripheral Stem Cell Transplantation for Hematologic Cancer
5. Fludarabine, Total-body Irradiation, Donor Peripheral Stem Cell Transplantation, and Donor White Blood Cell Infusions in Treating Patients With Hematologic Cancer
Related Studies:
Other Acute Lymphocytic Leukemia Clinical Trials
Other Maryland Clinical Trials
Other Bethesda Clinical Trials
A Pharmacokinetic and Pharmacodynamic Study of Vincristine in Children with Leukemia
|
|
|
|
|
|
|
|
